Inhibitors of the FcRn:IgG protein-protein interaction.
The neonatal Fc receptor, FcRn, is responsible for controlling the half-life of IgG antibodies. As a result, inhibitors of FcRn have been investigated as a possible way to modulate IgG half-lives. Such inhibitors could have possible applications in reducing autoantibody levels in autoimmune disease states. To date, monoclonal antibodies, engineered Fc domains, and short peptides have been reported to inhibit FcRn function and modulate IgG half-lives in vivo.
Low
Susan C
SC
Syntonix Pharmaceuticals Inc, A subsidiary of Biogen Idec, Waltham, MA 02451, USA.
Mezo
Adam R
AR
D000818:Animals; D000906:Antibodies / Q000235:genetics / Q000276:immunology; D006207:Half-Life; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology / Q000378:metabolism*; D011485:Protein Binding; D015202:Protein Engineering; D011961:Receptors, Fc / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000906:Antibodies; D015395:Histocompatibility Antigens Class I; D007074:Immunoglobulin G; D011961:Receptors, Fc; C100688:Fc receptor, neonatal